You are here

Brace Trial

This Australian-led study is the world’s largest trial on the off-target effects of Bacille Calmette-Guérin (BCG) vaccine. More than 6800 healthcare workers have been enrolled in Australia, Brazil, Spain, the Netherlands and the United Kingdom.                                                                                                                                                                                                                                                             

Welcome to the BRACE trial

This Australian-led study is the world’s largest trial on the off-target effects of Bacille Calmette-Guérin (BCG) vaccine. More than 6800 healthcare workers have been enrolled in Australia, Brazil, Spain, the Netherlands and the United Kingdom.

In addition to preventing severe tuberculosis (TB) in children, BCG vaccine has off-target (non-specific or immunomodulatory) effects. That’s why this multi-centre, randomised controlled clinical trial is working to determine:

Whether the BCG vaccine reduces the incidence of symptomatic and severe COVID-19.
If BCG vaccine reduces the impact of other respiratory illnesses and allergic diseases.
The immunological mechanisms that underlie BCG’s off-target effects, COVID-19 severity and risks.
The safety profile of BCG vaccination and revaccination in adults.
If BCG alters the acquisition of latent TB in healthcare workers.
Biomarkers predictive of COVID-19 risk, severity and vaccine efficacy.

What's new?

Brace participants

As the research team prepares for analysis, trial data generated so far includes:

  • Trial Symptom Tracker app entries – 337,000
  • Telephonista entries – 78,000
  • BRACE blood samples – 20,000
  • BCOS blood samples – 1600
  • Clinic visits – 21,000
  • Surveys sent – 22,000

The BRACE trial goes global

Hear from Professor Nigel Curtis, Chief Principal Investigator of the BRACE trial, as he discusses whether BCG vaccine might protect healthcare workers against COVID-19.

A cutting-edge study of BCG vaccine's off-target effects
Hands icon>6800
healthcare workers
Location icon36
study sites
World icon5
countries
People icon>360
researchers & staff
App icon>335K
app check-ins
Needle icon100
year-old vaccine

BRACE COVID-19-Specific vaccine sub-study (BCOS)

The BRACE trial has introduced a sub-study at selected sites in Australia and Brazil to investigate whether it’s possible to predict who remains susceptible to SARS-CoV-2 variants despite previous COVID-19 disease or COVID-19-specific vaccination. The sub-study will look at whether BCG vaccine, by boosting the immune system, improves the response to Pfizer, AstraZeneca and CoronaVac vaccines.

Find out more


News

Scientists in lab

Nov 2021
BRACE biosample and laboratory lead, Dr Nicole Messina, receives NHMRC Ideas Grant

Read more

BCG Vaccine

June 2021
MCRI’s BCG vaccine trial joins global race to better understand COVID-19 variants

Read more

needle

Oct 2020
Could BCG vaccine protect against COVID-19? UK recruitment begins

Read more

injection

May 2020
$10M grant enables MCRI’s BCG vaccine trial to expand internationally

Read more

hands

March 2020
MCRI to trial preventative vaccine for COVID-19 healthcare workers

Read more

View all news

Brace Trial partners